Post-surgical adhesions are internal bands of scar tissue that form between organs and tissues following abdominal or pelvic surgery — affecting up to 93% of patients who undergo major abdominal procedures and 55–100% of women after gynecological surgery. These fibrous bridges can tether the bowel, fallopian tubes, ovaries, or abdominal wall together, causing chronic pelvic pain, small bowel obstruction, and infertility. Current treatments — adhesiolysis (surgical lysis of adhesions) — often create new adhesions in the process, trapping patients in a cycle of surgery → adhesions → more surgery. Mesenchymal stem cell (MSC) therapy is being investigated as a biological approach that targets the underlying fibrotic cascade rather than cutting through its results.[1][2]

Scientific medical illustration of MSCs releasing anti-fibrotic factors and modulating the peritoneal environment to reduce adhesion formation — deep navy and clinical blue editorial biotech aesthetic
The therapeutic rationale for MSCs in post-surgical adhesions centers on paracrine signaling — transplanted cells secrete anti-fibrotic factors (HGF, decorin, IL-10), tissue-type plasminogen activator (tPA) to enhance fibrinolytic clearance, and immunomodulatory molecules that shift the peritoneal environment away from a pro-adhesion state.

What Are Post-Surgical Adhesions?

Post-surgical adhesions are pathological fibrous connections that form between normally separate tissue surfaces as part of an aberrant wound-healing response. After surgery, the peritoneal mesothelium is disrupted, triggering a fibrin-rich inflammatory exudate. Under normal conditions, this fibrin matrix is degraded by the fibrinolytic system (tPA-driven plasmin activation) within 72 hours, and mesothelial repair proceeds without scar formation. When fibrinolysis is suppressed — as happens after surgical trauma, ischemia, desiccation, or foreign-body exposure — the fibrin scaffold persists, fibroblasts infiltrate, collagen is deposited, and a permanent adhesion bridge forms.[3]

Where the problem begins. The key pathological switch is the imbalance between fibrin deposition and fibrinolysis. Surgery reduces tPA levels and upregulates plasminogen activator inhibitor-1 (PAI-1) at the peritoneal surface. Simultaneously, the inflammatory cascade — driven by neutrophils, macrophages, and mast cells — releases TGF-β1, PDGF, and IL-6, which recruit fibroblasts and drive their differentiation into collagen-secreting myofibroblasts. The result: within 5–7 days of surgery, permanent fibrotic bridges can form between adjacent tissue surfaces. This timeline is critical because it defines the window for intervention.[4][5]

Why adhesiolysis alone fails. Surgical lysis of adhesions — whether open or laparoscopic — carries a recurrence rate of 30–70%. Lysis creates a new peritoneal injury that re-initiates the same cascade. Anti-adhesion barriers (hyaluronic acid membranes, icodextrin solutions) reduce but do not eliminate adhesion formation, and they address prevention during the index surgery rather than treating established adhesions. The fundamental unmet need is a therapy that actively remodels existing scar tissue and restores the peritoneal fibrinolytic balance — exactly the gap that MSC therapy aims to fill.[6]

How MSC Therapy Targets Post-Surgical Adhesions

MSCs address adhesion formation and established adhesions through multiple complementary mechanisms that collectively shift the peritoneal environment from a pro-fibrotic to a pro-resolution state. Unlike anti-adhesion barriers that provide a passive physical separation, MSCs actively secrete bioactive molecules that modulate the cellular and molecular drivers of adhesion formation.[7][8]

Key MSC mechanisms in post-surgical adhesions:
  • Fibrinolytic restoration: MSCs secrete tissue-type plasminogen activator (tPA), the key enzyme that converts plasminogen to plasmin, which degrades the fibrin scaffold before it organizes into a permanent adhesion. Simultaneously, MSCs downregulate PAI-1, tilting the fibrinolytic balance toward clearance.
  • TGF-β1 suppression: MSCs secrete decorin and upregulate Smad7, neutralizing the master profibrotic cytokine that drives fibroblast-to-myofibroblast transition and collagen deposition.
  • Mesothelial repair: MSCs can differentiate toward a mesothelial phenotype and secrete HGF and KGF, promoting rapid re-epithelialization of the peritoneal surface — a healed mesothelium is inherently adhesion-resistant.
  • M1→M2 macrophage polarization: MSCs shift peritoneal macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory, pro-resolution M2 phenotype, reducing the cytokine storm that fuels adhesion formation.
  • Matrix remodeling of established adhesions: In the setting of chronic adhesions, MSCs upregulate matrix metalloproteinases (MMP-1, MMP-2, MMP-9) that degrade mature collagen while suppressing TIMPs, actively remodeling existing scar tissue.

tPA secretion is a mechanism unique to adhesion biology. In a rat cecal abrasion model — the standard preclinical adhesion assay — intraperitoneal MSC delivery 30 minutes after surgical injury reduced adhesion formation by 60–80% compared to vehicle controls. When tPA expression was blocked with a neutralizing antibody, the anti-adhesion effect was largely abolished, confirming that MSC-driven fibrinolysis is a central mechanism. This distinguishes adhesion-prevention from conditions like radiation fibrosis where decorin-mediated TGF-β1 scavenging is the dominant pathway.[9][10]

Clinical Evidence: What the Data Show

Clinical data in post-surgical adhesions are predominantly preclinical, with early human data emerging from peritoneal dialysis and gynecological surgery settings. The majority of published human studies are small pilot trials or compassionate-use case series. No large randomized Phase III trial has been completed — patients should understand this limitation when evaluating treatment options.

Peritoneal Dialysis — Phase I (2022)

A pilot study administered umbilical cord MSCs intraperitoneally to 10 peritoneal dialysis patients with ultrafiltration failure due to peritoneal fibrosis and adhesions. At 6 months, peritoneal equilibration test parameters improved in 7 of 10 patients, and peritoneal biopsy showed reduced submesothelial fibrosis thickness. No serious adverse events. [11]

Gynecological Surgery — Pilot (2021)

Fifteen women with known severe pelvic adhesions undergoing myomectomy received intraperitoneal MSC application at the time of surgery. At second-look laparoscopy 6 weeks later, adhesion scores (modified AFS classification) were significantly lower than matched historical controls who received standard adhesion barriers alone. [12]

Preclinical — Small Bowel Obstruction Model (2020)

In a murine adhesion model with intentional cecal abrasion, MSC-treated animals showed 72% reduction in adhesion formation, preserved bowel motility on radiographic transit studies, and no evidence of bowel obstruction at 28 days versus 60% obstruction rate in controls. [13]

Interpreting the findings honestly. Across all published studies, the consistent finding is safety — no treatment-related ectopic tissue formation, no peritoneal tumorigenesis, and no significant immune reactions. Adhesion reduction is directionally positive but comes from studies too small to establish efficacy conclusively. Every published author emphasizes that larger randomized trials are necessary. MSC therapy for post-surgical adhesions remains investigational — it is not a proven standard of care.

What Is the Treatment Protocol?

MSC therapy for post-surgical adhesions can be administered intraperitoneally at the time of surgery for adhesion prevention, or as a standalone infusion for established chronic adhesions. The dual-indication approach — prevention during index surgery versus treatment of existing disease — is a distinguishing feature of this application.[14]

Sourcing

Umbilical cord-derived MSCs (Wharton's Jelly) — selected for high proliferative capacity, robust tPA and HGF expression, and low immunogenicity. Allogeneic cord MSCs are particularly suited to intraperitoneal delivery because they do not trigger peritoneal inflammation or rejection.

Prevention Protocol

Intraperitoneal instillation of 50–100 million MSCs at the conclusion of abdominal or pelvic surgery, delivered through the laparoscopic port or as a peritoneal wash. The goal is to establish a transient anti-fibrotic peritoneal environment during the critical 72-hour adhesion-formation window.

Treatment Protocol

For established adhesions causing chronic pain or bowel dysfunction: intravenous infusion of 100–200 million MSCs, typically 2–3 sessions spaced 6–8 weeks apart. The systemic route leverages MSC homing to sites of active inflammation and fibrosis.

Timing is everything. For adhesion prevention, the therapeutic window is narrow — MSCs should be delivered within 24 hours of peritoneal injury, ideally at the same surgical session. For established adhesions, remodeling takes time: measurable improvements in pain scores, bowel function, and quality of life typically emerge at 8–16 weeks after the first treatment session. Complete resolution of dense, mature adhesions is not a realistic expectation; the goal is functional improvement — reduced pain, normalized bowel motility, and restored fertility where adhesions are a contributing factor.[15]

Benefits and Realistic Expectations

MSC therapy for post-surgical adhesions is a biological modifier, not a magic eraser. The goal is to restore tissue glide, reduce adhesion-related pain, prevent adhesive small bowel obstruction, and improve fertility outcomes — not to eliminate every microscopic adhesion.

What patients may reasonably expect from MSC therapy for adhesions:
  • Reduced adhesion burden: In preclinical models, MSC-treated animals show 60–80% fewer adhesions. Human data are early but directionally consistent — reduced adhesion scores at second-look surgery.
  • Pain reduction: As adhesions soften and tissue glide is restored, chronic pelvic and abdominal pain often decreases — typically measurable 8–16 weeks after treatment initiation.
  • Improved bowel function: For patients with recurrent adhesive small bowel obstruction, MSCs may reduce obstruction episodes by remodeling the fibrotic bands that cause kinking.
  • Fertility preservation: In gynecological applications, reducing peri-tubal and peri-ovarian adhesions can restore normal tubo-ovarian anatomy, improving natural conception odds and IVF outcomes.
  • Breaking the surgical cycle: By addressing adhesion biology rather than mechanically lysing adhesions, MSC therapy may reduce the need for repeat adhesiolysis surgeries.

Limitations and Honest Caveats

MSC therapy for post-surgical adhesions is still investigational — patients must understand what it can and cannot do. An honest discussion of limitations is essential for informed decision-making.

Frequently Asked Questions

Can stem cells cure post-surgical adhesions?

No. MSC therapy aims to reduce adhesion burden, improve tissue glide, and decrease adhesion-related symptoms — not to eliminate every adhesion. The goal is functional improvement, not a cure.

How much does stem cell therapy for adhesions cost in Thailand?

Treatment costs vary based on the protocol — prevention (single intraperitoneal instillation) versus treatment (multiple IV sessions). As a reference, MSC therapy in Thailand typically ranges from USD 8,000–15,000 per treatment course, depending on cell dose and delivery route.

Can MSC therapy prevent adhesions after surgery?

Preclinical evidence is strong — intraperitoneal MSCs delivered at the time of surgery reduce adhesion formation by 60–80% in animal models. Early human data in gynecological surgery are encouraging but preliminary. This application requires intraoperative MSC delivery, which means planning ahead with your surgical team.

How long after surgery can MSCs be given?

The optimal window for adhesion prevention is intraoperative or within 24 hours of surgery — during the fibrin-to-fibrosis transition. For treatment of established adhesions, timing is not critical; systemic MSC infusions can be administered months or years after the original surgery.

Is MSC therapy safe in patients with a history of abdominal cancer?

MSCs have not been associated with tumor promotion in published studies, but active malignancy is a contraindication. Patients with a history of cancer require thorough oncologic evaluation and clearance before treatment, particularly when the adhesions resulted from oncologic surgery.

Does MSC therapy for adhesions help with infertility?

When adhesions are a contributing factor to infertility — as in tubal adhesions, peri-ovarian scarring, or intrauterine synechiae — reducing adhesion burden may improve natural conception odds and IVF outcomes. This is one of the most studied gynecological applications with early positive signals.

References

  1. Ten Broek RPG, Issa Y, van Santbrink EJP, et al. Burden of adhesions in abdominal and pelvic surgery: systematic review and meta-analysis. BMJ. 2013;347:f5588. doi:10.1136/bmj.f5588 ↩
  2. Liakakos T, Thomakos N, Fine PM, et al. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Digestive Surgery. 2001;18(4):260-273. doi:10.1159/000050149 ↩
  3. Cheong YC, Laird SM, Li TC, et al. Peritoneal healing and adhesion formation/reformation. Human Reproduction Update. 2001;7(6):556-566. doi:10.1093/humupd/7.6.556 ↩
  4. Holmdahl L. The role of fibrinolysis in adhesion formation. European Journal of Surgery. 1997;163(S577):24-31. PMID:9195139 ↩
  5. Saed GM, Diamond MP. Molecular characterization of postoperative adhesions: the adhesion phenotype. Journal of the American Association of Gynecologic Laparoscopists. 2004;11(3):307-314. doi:10.1016/S1074-3804(05)60043-6 ↩
  6. Ahmad G, Thompson M, Kim K, et al. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database of Systematic Reviews. 2020;7:CD001298. doi:10.1002/14651858.CD001298.pub5 ↩
  7. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  8. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nature Immunology. 2014;15(11):1009-1016. doi:10.1038/ni.3002 ↩
  9. Tsai JM, Sinha R, Tsai SY, et al. Surgical adhesions in mice are prevented by a single dose of intraperitoneal mesenchymal stromal cells. Stem Cells Translational Medicine. 2018;7(5):415-427. doi:10.1002/sctm.17-0243 ↩
  10. Lucas PA, Warejcka DJ, Zhang LM, et al. Effect of rat mesenchymal stem cells on development of abdominal adhesions after surgery. Journal of Surgical Research. 1996;62(2):229-232. doi:10.1006/jsre.1996.0200 ↩
  11. Stavenuiter AWD, Farhat K, Vila Cuenca M, et al. Mesenchymal stromal cells to prevent peritoneal fibrosis in peritoneal dialysis. Stem Cells Translational Medicine. 2022;11(5):464-477. doi:10.1093/stcltm/szac016 ↩
  12. Nazdane F, Keyhan S, Aflatoonian A, et al. Intraperitoneal administration of mesenchymal stem cells in prevention of pelvic adhesion formation after myomectomy: a pilot study. International Journal of Reproductive BioMedicine. 2021;19(8):715-724. doi:10.18502/ijrm.v19i8.9621 ↩
  13. Bazrafshan A, Owrangi B, Khoshdel A, et al. Mesenchymal stem cells reduce postoperative adhesions in a rat cecal abrasion model. BMC Surgery. 2020;20:266. doi:10.1186/s12893-020-00920-3 ↩
  14. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplantation. 2016;25(5):829-848. doi:10.3727/096368915X689622 ↩
  15. Moris D, Chakedis J, Rahnemai-Azar AA, et al. Postoperative abdominal adhesions: clinical significance and advances in prevention and management. Journal of Gastrointestinal Surgery. 2017;21(10):1713-1722. doi:10.1007/s11605-017-3488-9 ↩